Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2021

View Archived Issues

Wuhan LL Science and Technology Development Co. patents P2X4 receptor antagonists

New GTPase KRAS inhibitors discovered at REVOLUTION Medicines

Kyorin Pharmaceutical and collaborators describe protein G9a inhibitors

Sinovent identifies new GTPase KRAS G12C mutant inhibitors

New CDK8 and/or CDK19 inhibitors synthesized at the Dana-Farber Cancer Institute

Karuna reports phase Ib data on KarXT in healthy elderly volunteers

XBiotech initiates trial of XB-2001 with chemotherapy for pancreatic cancer

First-in-human study of BDB-018 explores use in advanced solid tumors

Seal Rock begins phase I trial of SRT-015 for NASH

Titan reports in vivo data on TP-2021 implant in model of chronic pruritus

Mercaptor advances programs in COVID-19 brain inflammation and epilepsy

Study supports miR panel for diagnosing multiple sclerosis

CStone reports data on Gavreto in Chinese patients with advanced RET fusion-positive NSCLC

Fulcrum reports phase IIb data on losmapimod in FSHD

Sellas reports phase I data on galinpepimut-S with nivolumab in malignant pleural mesothelioma

Kaken begins Japanese phase I study of sofpironium bromide gel in primary palmoplantar hyperhidrosis

Back to the basics for new insights, with new technology

Applied Genetic Technologies reports 12-month data from phase I/II achromatopsia trials

Follicum discontinues development of FOL-005 for alopecia

Aravive advances phase Ib evaluation of AVB-500 with cabozantinib in clear cell renal cel carcinoma

Arcus provides interim analysis from ARC-7 study of domvanalimab combinations in NSCLC

Dosing begins in phase II study of ALPN-101 in SLE

First patient enters phase II study of TG-4001 with avelumab in HPV16-positive anogenital tumors

IN3BIO cleared to begin phase I/II trial of IN-01 for colorectal cancer in Bulgaria

Abivax reports phase IIa data on ABX-464 in rheumatoid arthritis

SelectImmune Pharma and Lonza collaborate to develop processes for novel immunotherapy protein NlpD

Carmot opens phase I study of dual GLP-1 and GIP receptor modulator CT-388

Bristol Myers Squibb exercises option to U.S. license for Prothena's PRX-005

4D Molecular Therapeutics reports pipeline update

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...